Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases
作者:Thomas F. Durand-Réville、Janelle Comita-Prevoir、Jing Zhang、Xiaoyun Wu、Tricia L. May-Dracka、Jan Antoinette C. Romero、Frank Wu、April Chen、Adam B. Shapiro、Nicole M. Carter、Sarah M. McLeod、Robert A. Giacobbe、Jeroen C. Verheijen、Sushmita D. Lahiri、Michael D. Sacco、Yu Chen、John P. O’Donnell、Alita A. Miller、John P. Mueller、Rubén A. Tommasi
DOI:10.1021/acs.jmedchem.0c00579
日期:2020.11.12
threat due to rapidly rising resistance toward β-lactamantibiotics. The hydrolytic enzymes called β-lactamases are responsible for a large proportion of the resistance phenotype. β-Lactamase inhibitors (BLIs) can be administered in combination with β-lactamantibiotics to negate the action of the β-lactamases, thereby restoring activity of the β-lactam. Newly developed BLIs offer some advantage over